[Federal Register Volume 64, Number 16 (Tuesday, January 26, 1999)]
[Notices]
[Pages 3952-3953]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-1709]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Pharmacy Compounding Advisory Committee Meeting; Amendment of 
Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an 
amendment to the notice of a meeting of the Pharmacy Compounding 
Advisory Committee which is scheduled for February 4 and 5, 1999. This 
meeting was announced in the Federal Register of January 6, 1999 (64 FR 
886). The amendment is being made to reflect a change in the Procedure 
portion of the meeting notice. There are no other changes. This 
amendment will be announced at the beginning of the open portion of the 
meeting.

FOR FURTHER INFORMATION CONTACT: Igor Cerny or Tony Slater, Center for 
Drug Evaluation and Research (HFD-21), Food and Drug Administration, 
5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, or FDA Advisory 
Committee Information Line, 1-800-741-8183 (301-443-0572 in the 
Washington, DC area), code 12440.

SUPPLEMENTARY INFORMATION: In the Federal Register of January 6, 1999 
(64 FR 886), FDA announced that a meeting of the Pharmacy Compounding 
Advisory Committee would be held on February 4 and 5, 1999. This 
amendment is being made to reschedule the time allotted for oral 
presentations from the public.
    On page 887, in the first column, the Procedure portion of this 
meeting notice is amended to read as follows:
    Procedure: Interested persons may present data, information or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by January 29, 
1999. Oral presentations from the public will be scheduled on February 
4, 1999, between approximately 11 a.m. and 12 m. for: Mild silver 
protein, 4-aminopyridine, and 3,4-diaminopyridine, and between 
approximately 3 p.m. and 4 p.m. for: Hydrazine; and on February 5, 
1999, between approximately 10 a.m. and 11 a.m. for: 
Dinitrochlorobenzene, diphenylcyclopropenone, and squaric acid dibutyl 
ester, and between approximately 3 p.m. and 4 p.m. for: 
Pentylenetetrazole, cyclandelate, and betahistine dihydrochloride. Time 
allotted for each presentation may be

[[Page 3953]]

limited. Those desiring to make a formal oral presentation should 
notify the contact person before January 29, 1999, and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time requested to make their 
presentation.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: January 20, 1999.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 99-1709 Filed 1-25-99; 8:45 am]
BILLING CODE 4160-01-F